Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery. Data comparing these two methods of VTE prophylaxis in patients undergoing pelvic/lower extremity orthopaedic surgery for malignancy are lacking, however, as compared to the data and guidelines present for VTE chemoprophylaxis after joint arthroplasty and hip fracture surgery. In this clinical trial, our specific aim is to compare the post operative incidence of VTE between patients receiving aspirin and LMWH after pelvic/lower extremity orthopaedic oncology procedures.

Official Title

Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology

Details

Keywords

Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding, Thromboembolism, Aspirin, Enoxaparin, Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe, LMWH for Soft Tissue Sarcoma, ASA for Soft Tissue Sarcoma

Eligibility

Locations

  • University of California Los Angeles Health
    Los Angeles California 90404 United States
  • University of Missouri-Columbia Cancer Care
    Columbia Missouri 65201 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Massachusetts General Hospital
ID
NCT03244020
Phase
Phase 4 research study
Study Type
Interventional
Participants
Expecting 2868 study participants
Last Updated